<DOC>
	<DOCNO>NCT00533624</DOCNO>
	<brief_summary>The comparison incidence G.I . toxicity Myfortic® vs. Cellcept® 150 sequential patient , 75 randomize Cellcept® 75 Myfortic® first second living decease donor renal transplant recipient .</brief_summary>
	<brief_title>Myfortic vs. Cellcept Kidney Transplant Recipients</brief_title>
	<detailed_description>Purpose Description : The purpose study determine gastrointestinal toxicity anti-rejection medication Myfortic® ( mycophenolic acid delay release ) less equivalent dos similar anti-rejection medication Cellcept® ( mycophenolate mofetil , MMF ) patient receive first second kidney transplant cadaver living donor . This study consist two randomized group , 75 patient give 3 dos Thymoglobullin ( Group I ) vs. 75 patient give 3 dos Thymoglobulin 2 dos Basiliximab ( Group II ) . Our standard maintenance protocol dose tacrolimus , IMPDH inhibitor ( vide infra ) one week course corticosteroid . Patients randomize receive Myfortic® 1,440 mg/day vs. Cellcept® 2,000 mg/day , two divide dos ( induced either IL-2 receptor inhibitor thymoglobulin ) . Tacrolimus dose 12-hour trough level 8-10 ng/ml . Methylprednisolone give per center protocol , wean dose level &lt; 0.1 mg/kg 3-6 month post-operatively .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>1 . Patient fully inform sign date IRB approval inform consent form willing follow study procedure extent study ( 12 month ) . Parent legal guardian must provide write consent patient &lt; 18 year age . 2 . Age 1875 year . 3 . Weight &gt; 40 kg . 4 . Primary secondary renal allograft : living decease donor . 5 . Negative standard crossmatch T cell . 6 . Women childbearing potential require negative qualitative serum pregnancy test agree use adequate method contraception study duration . 7 . Males female study equivalently become available transplantation use criterion . 1 . Patient previously receive receive organ transplant kidney . 2 . Patient receive ABO incompatible donor kidney . 3 . Recipient donor seropositive human immunodeficiency ( HIV ) , Hepatitis C virus , Hepatitis B virus antigenemia . 4 . Patient current malignancy history malignancy ( within past 5 year ) , except nonmetastatic basal squamous cell carcinoma skin treat successfully , carcinoma situ cervix treat successfully . 5 . Patients significant liver disease , define past 28 day continuously elevate AST ( SGOT ) and/or ALT ( SGPT ) level great 3 time upper value normal range center . 6 . Patient uncontrolled concomitant infection and/or severe diarrhea , vomit , active upper gastrointestinal tract malabsorption active peptic ulcer unstable medical condition could interfere study objective . 7 . Patient currently participate another clinical trial investigational drug 30 day prior transplant . 8 . Patient receive immunosuppressive agent prescribe study . 9 . Patient unable take medication orally via nasogastric tube morning second day follow completion transplant procedure ( i.e. , skin closure ) ( Group I ) . 10 . Patient receiving may require warfarin , fluvastatin , herbal supplement study . 11 . Concurrent use astemizole , pimozide , cisapride , terfenadine , ketoconazole . 12 . Patient known hypersensitivity tacrolimus , thymoglobulin , IL2 receptor inhibitor monoclonal antibody , sirolimus , MMF , Myfortic® , corticosteroid . 13 . Patient pregnant lactating . 14 . Patients screening/baseline ( within 96 hour transplant ) total white blood cell count &lt; 4000/mm3 ; platelet count &lt; 100,000/mm3 ; fast triglyceride &gt; 400 mg/dl ( &gt; 4.6 mmol/L ) ; fast total cholesterol &gt; 300 mg/dl ( &gt; 7.8 mmol/L ) ; fast HDLcholesterol &lt; 30 mg/dl ; fast LDLcholesterol &gt; 200 mg/dl . 15 . Patient unlikely comply visit schedule protocol . 16 . Patient form substance abuse , psychiatric disorder condition , opinion investigator , may invalidate communication investigator . If tacrolimus institute longer 5 day postoperatively .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Gastrointestinal toxicity</keyword>
</DOC>